Key Highlights
- Amide Technologies announces commercialization of a novel peptide manufacturing platform, significantly advancing the synthesis of long peptides.
- The company raised a total of $16.5 million in funding, including a $7.5 million Series A Extension led by Engine Ventures and Forcefield Venture Fund.
- Developed at MIT, Amide’s platform can synthesize peptides up to 120 amino acids long, surpassing traditional Solid Phase Peptide Synthesis limits.
- Amide is partnering with The Salk Institute and Velia Therapeutics to manufacture complex peptides for groundbreaking therapeutic applications.
- The new funding will be used to scale operations, build additional instrumentation, and launch pilot programs with pharmaceutical partners.
Source: Business Wire
Notable Quotes
- “Amide delivers on complex peptide orders that other vendors refuse because peptide sourcing shouldn’t stand in the way of discovery,” – Mark Simon, PhD, CEO at Amide Technologies
- “Amide is well-positioned to turbocharge today’s most exciting pharmaceutical frontiers,” – Reed Sturtevant, General Partner at Engine Ventures and Amide Board Member
- “Amide’s significant advances in peptide synthesis has allowed us to obtain synthetic versions of very long peptides which historically would have been intractable,” – Mack Flinspach, Executive Director, Protein Chemistry and Structural Biology at Velia, Inc
SoH's Take
Amide Technologies’ breakthrough in peptide synthesis marks a significant milestone in the biotech industry, addressing a long-standing challenge in peptide manufacturing. By extending the synthesis capability to peptides up to 120 amino acids, Amide not only surpasses the traditional limitations of Solid Phase Peptide Synthesis but also opens new avenues for therapeutic research and drug development. This innovation, coupled with substantial funding, positions Amide Technologies as a key player in accelerating pharmaceutical advancements. The collaboration with esteemed institutions and hiring of industry veterans further underscore the company’s commitment to leading the charge in peptide-based therapeutic solutions. The biotech sector should closely monitor Amide’s pioneering work, as it promises to bring forth novel therapeutic modalities and significantly reduce the time from drug conception to testing, a crucial factor in the fast-paced world of medical research and development.
